In Budd–Chiari with an identified MPN or PNH early in the course, what is your practical coordination strategy for cytoreductive/complement-inhibitor therapy with anticoagulation and endovascular management, and what clinical milestones prompt you to shift from repeat interventions to formal transplant evaluation?